Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China
· Delayed Price · Currency is CNY 12.10
+0.61 (5.31%)
May 13, 2025, 3:04 PM CST
Yifan Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 393.03 | 385.97 | -551.07 | 191.22 | 278.4 | 968.39 | Upgrade
|
| Depreciation & Amortization | 331.44 | 331.44 | 270.6 | 228.43 | 207.18 | 177.01 | Upgrade
|
| Other Amortization | 76.37 | 76.37 | 29.06 | 9.48 | 6.88 | 9.43 | Upgrade
|
| Loss (Gain) From Sale of Assets | -30.15 | -30.15 | -2.57 | 0.56 | -14.83 | 0.04 | Upgrade
|
| Asset Writedown & Restructuring Costs | 11.48 | 11.48 | 852.61 | 102.13 | 38.25 | 6.6 | Upgrade
|
| Loss (Gain) From Sale of Investments | 14.16 | 14.16 | 15.06 | 17.63 | 4.49 | -6.95 | Upgrade
|
| Provision & Write-off of Bad Debts | 61.63 | 61.63 | 60.47 | 29.12 | 21.34 | 8.19 | Upgrade
|
| Other Operating Activities | 31.43 | 37 | -237.89 | 38.44 | 56.52 | 40.34 | Upgrade
|
| Change in Accounts Receivable | -363.72 | -363.72 | -10.25 | -103.77 | -18.59 | -117.71 | Upgrade
|
| Change in Inventory | -147.75 | -147.75 | -109.39 | -167.1 | -80.48 | 21.86 | Upgrade
|
| Change in Accounts Payable | 239.99 | 239.99 | 62.88 | 156.63 | -99.34 | -49.22 | Upgrade
|
| Change in Other Net Operating Assets | 19.71 | 19.71 | 21.79 | 23.15 | -10.3 | 82.7 | Upgrade
|
| Operating Cash Flow | 642.23 | 640.73 | 348.58 | 472.07 | 301.23 | 1,109 | Upgrade
|
| Operating Cash Flow Growth | 21.78% | 83.81% | -26.16% | 56.71% | -72.82% | 18.27% | Upgrade
|
| Capital Expenditures | -607.57 | -628.16 | -504.09 | -542.27 | -571.74 | -715.71 | Upgrade
|
| Sale of Property, Plant & Equipment | 3.6 | 0.32 | 5.02 | 7.84 | 17.7 | 0.96 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -42 | -39.81 | Upgrade
|
| Divestitures | 0.46 | 5.29 | 1.06 | 1.2 | 15.9 | 3 | Upgrade
|
| Investment in Securities | 25 | 75 | -39.13 | -137.58 | 66.6 | -26 | Upgrade
|
| Other Investing Activities | 2.54 | 2.67 | 4.3 | 0.65 | 5.64 | 7.01 | Upgrade
|
| Investing Cash Flow | -575.97 | -544.88 | -532.84 | -670.17 | -507.89 | -770.55 | Upgrade
|
| Long-Term Debt Issued | - | 2,001 | 1,855 | 1,789 | 2,928 | 1,957 | Upgrade
|
| Long-Term Debt Repaid | - | -1,709 | -2,044 | -1,897 | -2,448 | -2,210 | Upgrade
|
| Net Debt Issued (Repaid) | 180.33 | 291.87 | -189.38 | -107.72 | 480.27 | -252.97 | Upgrade
|
| Issuance of Common Stock | - | - | - | 0.85 | 1 | - | Upgrade
|
| Repurchase of Common Stock | - | - | -38 | -53.56 | -121.47 | -1.62 | Upgrade
|
| Common Dividends Paid | -192.78 | -194.81 | -72.47 | -86.38 | -138.39 | -201.98 | Upgrade
|
| Other Financing Activities | 24.94 | 15.67 | 330.62 | 234.15 | 0.75 | -111.38 | Upgrade
|
| Financing Cash Flow | 12.49 | 112.73 | 30.78 | -12.66 | 222.16 | -567.95 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.8 | -3.69 | 14.59 | 59.56 | -20.85 | 1.33 | Upgrade
|
| Net Cash Flow | 79.55 | 204.89 | -138.88 | -151.2 | -5.36 | -228.66 | Upgrade
|
| Free Cash Flow | 34.66 | 12.57 | -155.5 | -70.21 | -270.51 | 392.8 | Upgrade
|
| Free Cash Flow Growth | 212.58% | - | - | - | - | 451.93% | Upgrade
|
| Free Cash Flow Margin | 0.67% | 0.24% | -3.82% | -1.83% | -6.13% | 7.27% | Upgrade
|
| Free Cash Flow Per Share | 0.03 | 0.01 | -0.13 | -0.06 | -0.22 | 0.32 | Upgrade
|
| Cash Income Tax Paid | 380.31 | 321.69 | 362.22 | 91.5 | 220.66 | 456.31 | Upgrade
|
| Levered Free Cash Flow | -130.48 | -171.28 | -160.61 | -347 | -430.33 | -173.92 | Upgrade
|
| Unlevered Free Cash Flow | -89.35 | -128.1 | -113.39 | -293.35 | -383.71 | -129.5 | Upgrade
|
| Change in Net Working Capital | 53.74 | 111.56 | -90.36 | 96.08 | 183.23 | 316.77 | Upgrade
|
Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.